


# 既治療症例におけるTMC435の治療効果

%(nN)	TMC435 12PR48 N=66	TMC435 24PR48 N=68	TMC435 48PR48 N=65	All TMC435 N=199	Placebo PR48 N=66
Relapser					
EoT	92 (24/26)	93 (25/27)	92 (24/26)	92 (73/79)	70 (19/27)
SVR4	<b>84</b> (21/25)	<b>93</b> (25/27)	<b>85</b> (22/26)	<b>87</b> (68/78)	<b>50</b> (12/24)
Partial Responder					
EoT	78 (18/23)	83 (20/24)	86 (19/22)	83 (57/69)	17 (4/23)
SVR4	<b>64</b> (14/22)	<b>86</b> (18/22)	<b>82</b> (18/22)	<b>77</b> (50/65)	<b>11</b> (2/18)
Null Responder					
EoT	65 (11/17)	71 (12/17)	77 (13/17)	71 (36/51)	25 (4/16)
SVR4	<b>56</b> (9/16)	<b>60</b> (9/15)	<b>56</b> (9/16)	<b>57</b> (27/47)	<b>23</b> (3/13)

# MK-7009: Study Design



**Primary hypothesis: RVR rates for at least 1 MK-7009-treated group superior to control**

# MK-7009のRVRとSVR


MK-7009 Dose group	RVR (Full Analysis set)	% RVR	SVR (Full Analysis Set)	% SVR
300mg bid	12/18	67	11/18	61
600 mg bid	16/20	80	16/20	80
600 mg qd	12/17	71	14/18	78
800 mg qd	16/19	84	16/19	84
placebo	1/19	5	12/19	63

- SVR for QD and high BID doses of MK7009 numerically higher than placebo
  - Placebo SVR rate higher than expected /historical rate

# 新しい抗HCV剤+新しい抗HCV剤:

プロテアーゼ阻害剤  
ポリメラーゼ阻害剤  
NS5A阻害剤


# ポリメラーゼ阻害剤(RG7128)とプロテアーゼ阻害剤(RG7227)の同時投与による抗ウイルス効果



# DAAsの開発状況




	NS3 PI	NS5A Inh	NS5B Nuc	NS5B NN
Roche	Danoprevir		R7128	
Vertex	Telaprevir			VX-222
BMS	BMS650032	BMS790052		
Boehringer	BI201335			BI207127
Gilead	GS-9256			GS-9190
Idenix	IDX320		IDX184	
Abbott	ABT450			ABT072
Pharmasset			PSI-938+PSI-7977	

# GS-9256+Tegobuvir Study



- GS 9256 75mg BID, Tegobuvir 40 mg BID,
- RBV 1000-1200 mg/day, Peginterferon alfa-2a 180 mcg SC QW
- Safety and virologic monitoring 2-3\* per week
- Serial PK evaluated at week 3 or 4


# GS-9256+Tegobuvirの抗ウイルス効果





# NS5A阻害剤 (BMS-790054)+プロテアーゼ阻害剤 (BMS-650032) の臨床試験

Subjects: **genotype 1, null responders** (< 2log decline in HCV RNA following 12 weeks of treatment with PegIFN/RBV)



- BMS-790052 (NS5A inhibitor) 60mg PO QD
- BMS-650032 (NS3 protease inhibitor) 600mg PO BID
- PegIFN alfa-2a 180 µg SC pnce weekly
- RBV 1000-1200 mg daily in 2 divided doses, according to body wight  
PO=orally; SC=Subcutaneously

# HCV RNAの変化

Group A:  
BMS-790054+BMS-650032

Group B:  
BMS-790054+BMS-650032+Peg/RBV

